Stockreport

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting

Ardelyx, Inc.  (ARDX) 
Last ardelyx, inc. earnings: 3/6 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ardelyx.com/investor-relations
PDF IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing [Read more]